 EMERYVILLE, Calif., Feb. 01, 2021 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA fenfluramine oral solution is now available in Germany for the treatment of seizures associated with Dravet syndrome in patients aged two years and older, as an add-on therapy to existing anti-epileptic medications. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy and is marked by severe refractory seizures, frequent medical emergencies, significant cognitive and behavioral impairments, and an increased risk of sudden premature death SUDEP. 